European Medicines Agency issues advice on sotrovimab (VIR-7831) for COVID-19

Following a review, the agency has concluded that sotrovimab, an investigation monoclonal antibody, can be used to treat confirmed COVID-19 in adults and adolescents (> 40 kg) who do not require supplemental oxygen therapy and are at risk of progressing to severe COVID-19.

SPS commentary:

A planned interim analysis of a supporting study indicated that sotrovimab reduced the risk of hospitalisation for more than 24 hours or death by 85% versus placebo: hospitalisation for more than 24 hours or death occurred in 1% (3 out of 291) of patients who received sotrovimab and 7% (21 out of 292) of those who received placebo.

European Medicines Agency